The drug "was well-tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class," according to the statement.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/fBmCEU0
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment